Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$3.19 +0.9%	$2.83	$1.69 ▼ $6.90	$8.23M	2.04	170,314 shs	43,486 shs
CSCI COSCIENS Biopharma	$3.29 +21.9%	$3.56	$1.96 ▼ $6.18	$10.35M	0.91	5,211 shs	91,783 shs
PRTG Portage Biotech	$9.11 +2.8%	$6.62	$2.81 ▼ $23.01	$9.55M	0.24	49,603 shs	15,712 shs
VGLS VG Life Sciences	$0.00	$0.00	$0.00 ▼ $0.00	$2.11M	1.67	2.60 million shs	100,300 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	+0.95%	+2.24%	+15.16%	+57.92%	-3.92%
CSCI COSCIENS Biopharma	+24.91%	+11.90%	-20.72%	-7.32%	+328,999,900.00%
PRTG Portage Biotech	+2.82%	+4.95%	+49.34%	+15.46%	+243.77%
VGLS VG Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELZ Creative Medical Technology	1.5175 of 5 stars	0.0	5.0	0.0	0.0	3.9	0.0	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	0.533 of 5 stars	0.0	5.0	0.0	0.0	0.0	1.7	0.0
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
PRTG Portage Biotech	0.00	N/A	N/A	N/A
VGLS VG Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VGLS, PRTG, CELZ, and CSCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/12/2025	CELZ Creative Medical Technology	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELZ Creative Medical Technology	$10K	823.02	N/A	N/A	$2.65 per share	1.20
CSCI COSCIENS Biopharma	$9.59M	1.08	N/A	N/A	$2.26 per share	1.46
PRTG Portage Biotech	N/A	N/A	N/A	N/A	($0.79) per share	N/A
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELZ Creative Medical Technology	-$5.49M	-$3.18	N/A	N/A	N/A	N/A	-82.99%	-79.49%	N/A
CSCI COSCIENS Biopharma	-$15.31M	-$6.01	N/A	∞	N/A	-199.55%	-149.49%	-54.80%	11/11/2025 (Estimated)
PRTG Portage Biotech	-$6.77M	-$41.65	N/A	∞	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)
VGLS VG Life Sciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VGLS, PRTG, CELZ, and CSCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	$2.75 million
8/8/2025	Q2 2025	CELZ Creative Medical Technology	-$0.63	-$0.48	+$0.15	-$0.48	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	N/A
VGLS VG Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELZ Creative Medical Technology	N/A	23.86	23.86
CSCI COSCIENS Biopharma	N/A	2.98	2.54
PRTG Portage Biotech	N/A	2.02	2.02
VGLS VG Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELZ Creative Medical Technology	1.42%
CSCI COSCIENS Biopharma	0.73%
PRTG Portage Biotech	13.36%
VGLS VG Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
CELZ Creative Medical Technology	2.80%
CSCI COSCIENS Biopharma	0.10%
PRTG Portage Biotech	42.07%
VGLS VG Life Sciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELZ Creative Medical Technology	5	2.58 million	2.51 million	Not Optionable
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
PRTG Portage Biotech	6	1.05 million	608,000	Optionable
VGLS VG Life Sciences	1	21.10 billion	N/A	Not Optionable

VGLS, PRTG, CELZ, and CSCI Headlines

Recent News About These Companies

VGLS VG Life Sciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Camfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel Seals

October 31, 2024 | markets.businessinsider.com

VG Life Sciences Inc.

September 14, 2024 | barrons.com

VG Life Sciences, Inc. Increases Authorized Shares

August 16, 2024 | br.advfn.com

VG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10

August 16, 2024 | br.advfn.com

VG Life Sciences Inc. (VGLS)

March 1, 2024 | finance.yahoo.com

VG Life Sciences Stock (OTC:VGLS), Insider Trading Activity

February 27, 2024 | benzinga.com

Emerging from a Recent Pullback, Life Sciences Has a Pulse

January 18, 2024 | globest.comG

VG Life Sciences Inc VGLS

November 16, 2023 | morningstar.comM

Report warns of 'oversupply' of life sciences real estate

September 17, 2023 | bizjournals.com

VGLS VG Life Sciences Inc.

February 16, 2023 | seekingalpha.com

The best Life is Strange game is on PlayStation Plus right now – and it’s not what you think

January 26, 2023 | vg247.comV

New MarketBeat Followers Over Time

Media Sentiment Over Time

VGLS, PRTG, CELZ, and CSCI Company Descriptions

Creative Medical Technology NASDAQ:CELZ

$3.19 +0.03 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.15 -0.04 (-1.25%)

As of 08/22/2025 07:42 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

COSCIENS Biopharma NASDAQ:CSCI

$3.29 +0.59 (+21.85%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.29 0.00 (0.00%)

As of 08/22/2025 07:39 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Portage Biotech NASDAQ:PRTG

$9.11 +0.25 (+2.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.48 +0.37 (+4.01%)

As of 08/22/2025 07:37 PM Eastern

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)

As of 08/22/2025 10:45 AM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time